Celcuity Inc. (CELC) - Q2 2024 10-Q Summary
Business Context and Reporting Period
Celcuity Inc. is a clinical-stage biotechnology company focused on developing targeted therapies for solid tumors, led by its pan-PI3K/mTOR inhibitor, gedatolisib. This report covers the quarterly period ended June 30, 2024. The company has not generated any revenue to date and continues to incur significant research and development expenses.
Key Financial Metrics
| Metric | Q2 2024 (3 Months) | YTD 2024 (6 Months) | Balance Sheet (June 30, 2024) |
|---|---|---|---|
| Revenue | $0 | $0 | N/A |
| Net Loss | $(23.7) million | $(45.3) million | N/A |
| Operating Expenses | $(24.3) million | $(46.8) million | N/A |
| Cash & Cash Equivalents | N/A | N/A | $30.5 million |
| Short-Term Investments | N/A | N/A | $252.6 million |
| Total Liquidity | N/A | N/A | $283.1 million |
| Long-Term Debt (Net) | N/A | N/A | $96.2 million |
| Accumulated Deficit | N/A | N/A | $(205.4) million |
Material Changes vs. Prior Period
- Increased Operating Expenses: Total operating expenses rose 61% year-over-year for Q2 2024 ($24.3M vs. $15.1M) and 69% for the six-month period ($46.8M vs. $27.6M). This increase is primarily driven by R&D costs associated with the VIKTORIA-1 Phase 3 and CELC-G-201 Phase 1b/2 clinical trials.
- Net Loss Expansion: Net loss increased to $23.7M in Q2 2024 from $14.6M in Q2 2023. For the six months ended June 30, 2024, the net loss was $45.3M compared to $26.5M in the prior year.
- Debt Restructuring: In May 2024, the company entered into an Amended and Restated Loan Agreement, increasing total borrowings to $100 million (principal) with additional tranches available upon milestone achievement. This resulted in higher interest expense ($2.3M in Q2 2024 vs. $1.3M in Q2 2023).
- Capital Raising: The company raised approximately $129 million in gross proceeds during the quarter through a follow-on equity offering ($60M gross), ATM offerings ($7.6M gross), and new debt financing ($61.7M new borrowings).
Guidance, Outlook, and Risks
- Clinical Outlook:
- VIKTORIA-1 (Phase 3): Enrollment for the PIK3CA wild-type cohort is >80% complete, with topline data expected in late Q4 2024 or Q1 2025.
- CELC-G-201 (Phase 1b/2): Evaluating gedatolisib with darolutamide in prostate cancer; first patient dosed in February 2024.
- VIKTORIA-2 (Phase 3): Planned initiation in Q2 2025 for first-line breast cancer treatment.
- Liquidity: Management believes current cash, investments, and available debt borrowings are sufficient to fund operations through 2026.
- Risks: Key risks include the uncertainty of clinical trial outcomes, the need for substantial additional financing, and the complexity of regulatory approval. The company has no revenue and relies entirely on capital markets.
Investor Verification Checklist
- Verify the enrollment progress and data readout timeline for the VIKTORIA-1 Phase 3 trial, specifically the PIK3CA wild-type cohort.
- Review the terms of the Amended and Restated Loan Agreement, specifically the milestone triggers for the remaining $80M in available tranches and the associated non-utilization fees.
- Monitor the burn rate relative to the $283.1M liquidity position to confirm the runway through 2026.
- Assess the impact of the increased debt load on future interest expenses and potential dilution from warrant exercises and conversion rights.